UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.830

Sortiert nach

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Journal of clinical oncology, 2020-12, Vol.38 (36), p.4274-4282

2020

Volltextzugriff (PDF)

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

Cancer discovery, 2017-06, Vol.7 (6), p.620-629

2017

Volltextzugriff (PDF)

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors

Journal of medicinal chemistry, 2017-02, Vol.60 (4), p.1262-1271

2017

Volltextzugriff (PDF)

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib

Molecular cancer therapeutics, 2014-02, Vol.13 (2), p.433-443

2014

Volltextzugriff (PDF)

Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model

Nature medicine, 2004-11, Vol.10 (11), p.1257-1260

2004

Volltextzugriff (PDF)

Synergistic Therapy of a Naturally Inspired Glycopolymer‐Based Biomimetic Nanomedicine Harnessing Tumor Genomic Instability

Advanced materials (Weinheim), 2021-11, Vol.33 (45), p.e2104594-n/a

2021

Volltextzugriff (PDF)

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

Cell reports (Cambridge), 2018-12, Vol.25 (11), p.2972-2980.e5

2018

Volltextzugriff (PDF)

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Molecular cancer therapeutics, 2020-01, Vol.19 (1), p.13-25

2020

Volltextzugriff (PDF)

From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity

Bioorganic & medicinal chemistry, 2021-07, Vol.42, p.116266-116266, Article 116266

2021

Volltextzugriff (PDF)

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Cancer research (Chicago, Ill.), 2012-11, Vol.72 (21), p.5588-5599

2012

Volltextzugriff (PDF)

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study

Journal of thoracic oncology, 2019-08, Vol.14 (8), p.1447-1457

2019

Volltextzugriff (PDF)

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

Nature communications, 2018-05, Vol.9 (1), p.1849-14, Article 1849

2018

Volltextzugriff (PDF)

Discovery and Characterization of (8S,9R)‑5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl‑1H‑1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro‑3H‑pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent

Journal of medicinal chemistry, 2016-01, Vol.59 (1), p.335-357

2016

Volltextzugriff (PDF)

Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies

Journal of enzyme inhibition and medicinal chemistry, 2022-12, Vol.37 (1), p.299-314

2022

Volltextzugriff (PDF)

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition

The Journal of pharmacology and experimental therapeutics, 2014-06, Vol.349 (3), p.408

2014

Volltextzugriff (PDF)

Some recent approaches of biologically active substituted pyridazine and phthalazine drugs

Current medicinal chemistry, 2012-06, Vol.19 (18), p.2984

Asif, M

2012

Volltextzugriff (PDF)

BRCAness revisited

Nature reviews. Cancer, 2016-02, Vol.16 (2), p.110

2016

Volltextzugriff (PDF)

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Nature communications, 2019-11, Vol.10 (1), p.5065-15, Article 5065

2019

Volltextzugriff (PDF)

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Cancer discovery, 2019-05, Vol.9 (5), p.646-661

2019

Volltextzugriff (PDF)

NAD+ Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair

Cell metabolism, 2016-10, Vol.24 (4), p.566-581

2016

Volltextzugriff (PDF)

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (14), p.3870-3884

2017

Volltextzugriff (PDF)

Olaparib: First Global Approval

Drugs (New York, N.Y.), 2015-02, Vol.75 (2), p.231-240

Deeks, Emma D.

2015

Volltextzugriff (PDF)

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks

Nature communications, 2019-01, Vol.10 (1), p.87-18, Article 87

2019

Volltextzugriff (PDF)

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

Journal of medicinal chemistry, 2008-10, Vol.51 (20), p.6581-6591

2008

Volltextzugriff (PDF)

1 – 25 von 1.830

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.657)
Mit Volltextzugriff
(1.454)

Publikationsform

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.558)
Life Sciences & Biomedicine
(1.475)
Phthalazines - Pharmacology
(1.378)
Humans
(1.247)
Animals
(956)
Pharmacology & Pharmacy
(634)
Female
(628)
Male
(560)
Biological And Medical Sciences
(505)
Piperazines - Pharmacology
(479)
Medical Sciences
(474)
Cell Line, Tumor
(454)
Mice
(438)
Oncology
(405)
Pharmacology. Drug Treatments
(401)
Phthalazines - Therapeutic Use
(355)
Poly Polymerase Inhibitors - Pharmacology
(331)
Rats
(283)
Antineoplastic Agents - Pharmacology
(271)
Chemistry, Medicinal
(264)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib

Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model

Synergistic Therapy of a Naturally Inspired Glycopolymer‐Based Biomimetic Nanomedicine Harnessing Tumor Genomic Instability

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non- BRCA1/2 -Mutant Cancers

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition

Some recent approaches of biologically active substituted pyridazine and phthalazine drugs

BRCAness revisited

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

NAD+ Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

Olaparib: First Global Approval

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

Suchergebnisse filtern